By Chelsea Naso ( August 6, 2015, 5:09 PM EDT) -- Venture capital-backed Aimmune Therapeutics Inc., led by Latham & Watkins LLP, saw its shares soar in its trading debut Thursday after the severe allergy biotech topped expectations with a $160 million initial public offering....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.